Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

REUTERS — The U.S. Centers for Disease Control and Prevention has ended its emergency response for H5N1 avian flu, owing to a decline in animal infections and no reports of human cases since February.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...